Novo Nordisk Rises 0.64% as Trading Volume Plummets to $510M Rank 187th Amid Fraud Allegations

On September 3, 2025, Novo Nordisk (NVO) closed with a 0.64% increase, despite a 21.75% drop in trading volume to $0.51 billion, ranking 187th in market activity. The stock’s performance came amid ongoing legal scrutiny following a class-action lawsuit alleging securities fraud between May 7 and July 28, 2025. The lawsuit claims the company overstated its growth potential in the GLP-1 market while concealing risks related to compounded GLP-1 competition and slower-than-expected market expansion.

The case alleges that Novo’s public statements during this period were misleading, particularly regarding its ability to capture market share with Wegovy and Ozempic. The lawsuit highlights the company’s failure to disclose the impact of personalized compounded GLP-1 treatments, which reduced the likelihood of patients switching to Novo’s branded alternatives. These alleged misrepresentations led to a sharp decline in Novo’s stock price after it revised its 2025 earnings guidance on July 29, citing lower growth expectations for its key products.

Investors who held shares during the specified period are being urged to assess their eligibility for potential legal action. The litigation, led by Levi & Korsinsky LLP, focuses on recovering losses from shareholders affected by the alleged misconduct. While the firm’s historical success in securities cases is noted, the outcome of this action remains pending. The recent volatility underscores the ongoing legal and market challenges facing Novo as it navigates competitive pressures in the diabetes and obesity drug sector.